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Because of their essentiality for DNA replication, transcription, and repair, type II topoisomerases are tar-
gets for antibacterial and anticancer drugs. There are two type II topoisomerases in humans, topoisomer-
ase IIa (TOP2A) and topoisomerase IIb (TOP2B), and two in bacteria, gyrase and topoisomerase IV.
Inhibition of one or both of the human type II topoisomerases by antibacterial compounds targeting their
bacterial counterparts could result in toxicity. In addition, side effects of anticancer drugs targeting
TOP2A could result from inhibition of TOP2B. A simple and rapid biochemical assay for the activity of
TOP2A and TOP2B would be advantageous for screening for novel inhibitors, testing them for selectivity
for one enzyme over the other, and testing for potential toxicity of antibacterial type II topoisomerases
mediated by human topoisomerase II inhibition. In this paper, we show that a previously reported
high-throughput, ﬂuorescence anisotropy-based assay for ATP-dependent relaxation of supercoiled
DNA by human TOP2A can also be used under identical conditions for human TOP2B. We used this assay
to compare the potencies versus both enzymes of 19 compounds reported in the literature to inhibit
human and/or bacterial type II topoisomerases. We also used the assay to investigate the effect of ATP
concentration on inhibitor potencies.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.By making double-stranded breaks in the DNA backbone, pass-
ing another length of the DNA through the break, and then reseal-
ing it, type II topoisomerases (TopoIIs)2 alter the degree of
supercoiling of DNA in a process that requires ATP hydrolysis [1].
The essentiality of TopoIIs for cellular processes involving DNA such
as replication, transcription, chromosome segregation, and recombi-
nation in both eukaryotes and prokaryotes [2] makes these enzymes
attractive targets for both anticancer [3] and antibacterial drugs
[4,5]. For example, cancer chemotherapeutic epipodophyllotoxins
such as etoposide target human TopoII, and the antibacterial ﬂuoro-
quinolones such as ciproﬂoxacin target bacterial TopoIIs (gyrase and
TopoIV). There is a need to identify new TopoII-targeting drugs withhigh speciﬁcity in order to reduce cytotoxic and genotoxic side
effects.
Human cells have two TOP2 enzymes, TOP2A and TOP2B [6,7].
They share 68% amino acid identity and 77% similarity [8]. TOP2A
and TOP2B are expressed at similar levels in dividing cells, includ-
ing tumors, whereas TOP2B is the more abundant TopoII in noncy-
cling cells [9]. TOP2A is essential for survival of cells in vitro [10]. In
contrast, TOP2B is not essential for cells in vitro [11], but mice lack-
ing TOP2B are not viable because TOP2B is important for neuronal
differentiation [12,13]. Murine Top2B/ cells are resistant to the
cytotoxicity of acridines and mitoxantrone [14], and the genotoxi-
city of etoposide is TOP2B dependent [15–17]. Also, TOP2B is
implicated in the cardiotoxicity of doxorubicin [18]. Consistent
with this, inhibition of TOP2B by dexrazoxane (ICRF 187) is protec-
tive against doxorubicin cardiotoxicity [19]. Differential inhibition
of TOP2A over TOP2B may therefore be a desirable property for no-
vel anticancer drugs [16,20]. Current agents against TopoII were
not selected for isoform speciﬁcity. Some of these agents lack
selectivity [21–23] while others have been reported to be selective
inhibitors of one of the enzymes, including razoxane (ICRF 159),
ICRF 193, and merbarone, which were more potent inhibitors
in vitro of TOP2A [21,24], and XK469, which was a more potent
inhibitor of TOP2B [25].
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inhibiting TOP2A and TOP2B isoforms in cells, so for future drug
development it will be important to measure the potencies of no-
vel TOP2-directed anticancer drugs toward both enzymes. It is also
important to test for inhibition of TOP2A and TOP2B by novel anti-
bacterial TopoII inhibitors because unintended inhibition of the
human enzymes could cause side effects, including genotoxicity
[15,16,26,27]. It is desirable to make such measurements of TopoII
inhibition using puriﬁed topoisomerase enzymes to simplify the
interpretation of inhibitor potencies.
Measurements of puriﬁed TopoII activity typically involve using
gel electrophoresis to separate DNA topoisomers, either plasmids
differing in their degree of supercoiling or single versus concate-
nated kinetoplast DNA circles (decatenation). This low-throughput
method is not suitable either for high-throughput screening for no-
vel TopoII inhibitors or for convenient measurement of inhibitory
potencies for many compounds simultaneously. A simple and con-
venient high-throughput method using a ﬂuorescence anisotropy
measurement in microtiter plates has been described previously
for measuring supercoiling of relaxed plasmid DNA by gyrase
[28] or ATP-dependent relaxation of supercoiled plasmid DNA by
TOP2A [29]. This method, performed in homogeneous solution, re-
quires only addition of reagents to the wells of the plate, without
heating, washing, or ﬁltration, followed by measurement with a
ﬂuorescence polarization-equipped plate reader. Another high-
throughput-compatible topoisomerase assay was recently re-
ported [30].
In this paper, we show that the high-throughput ﬂuorescence
anisotropy-based assay for ATP-dependent relaxation of super-
coiled DNA previously described for activity measurements of
puriﬁed human TOP2A [29] can also be used under identical condi-
tions for puriﬁed human TOP2B. We were therefore able to per-
form, in just a few hours, a side-by-side comparison of inhibitory
potencies toward TOP2A- and TOP2B-catalyzed ATP-dependent
supercoiled DNA relaxation for a set of 19 diverse TopoII inhibitors,
including both catalytic inhibitors and topoisomerase poisons, as
well as for a set of 75 analogs of a novel inhibitor of bacterial type
II topoisomerases. In addition, we investigated the effect of ATP
concentration on the potencies of some of the inhibitors toward
TOP2B, novel information that contributes to investigations of
the mechanisms of inhibitors with respect to the topoisomerase
catalytic cycle.Materials and methods
Chemicals
Commercially available inhibitors were purchased from Sigma
(St. Louis, MO), except for gemiﬂoxacin and teniposide, which were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Pro-
prietary compounds were prepared by AstraZeneca. Compounds
were dissolved in dimethyl sulfoxide (DMSO) at 10 or 20 mM.
Stock solutions were stored at 20 C.
Enzymes
Human TOP2A was purchased from Affymetrix/USB Corp.
(Cleveland, OH). Human TOP2B was puriﬁed as previously de-
scribed [31].
Fluorescence anisotropy assay for ATP-dependent relaxation of
supercoiled plasmid DNA, IC50 measurements, and calculations
Two-fold serial dilutions of compounds were prepared in
DMSO. Two overlapping sets of serial dilutions of each compoundwere present on each replicate plate, with ﬁnal concentrations in
the assays ranging from 200 lM to 0.39 lM and from 2 lM to
3.9 nM, except that for gemiﬂoxacin and levoﬂoxacin, the concen-
tration ranges were twice as high. The ﬁnal DMSO concentration in
the assays was 2% by volume. The assay conditions, methods, plate
reader settings, and calculations were described previously [29].
All measurements were made at room temperature, about 21 C.
Inhibitors and enzymes were incubated together for 30 min at
2 their ﬁnal concentrations prior to initiation of the reactions
with a solution of ATP and DNA at 2 their ﬁnal concentrations.
The TOP2B concentration in the assay was 90 ng/ml (0.5 nMmono-
mer). TOP2A and TOP2B assays were performed at the same time
using replicate assay plates. A third replicate plate was used for
interference correction [32]. Data points were excluded from IC50
curve ﬁtting analysis if the correction procedure necessitated a
greater than 2-fold change in the value of a measurement. When
IC50s fell within the ranges of both sets of dilutions, the average
IC50 was calculated. Measurements were made on 3 separate days.
The maximal range of triplicate IC50 measurements was 3-fold
(highest/lowest IC50), and the maximum percentage coefﬁcient of
variation (100  standard deviation/mean) was 64%.
Each plate containing enzyme had 32 wells with no enzyme or
inhibitor (MIN) and 32 wells with enzyme but no inhibitor (MAX).
The DMSO concentration was 2% by volume in MAX andMIN wells.
The average MIN and MAX for each plate were used to calculate
percentage inhibition. Plate-wise Z0 scores [33] were 0.74 ± 0.06
for TOP2A and 0.77 ± 0.04 for TOP2B (mean ± standard deviation,
n = 6). The average anisotropy difference between plate-averaged
MAXs and MINs was 0.10 ± 0.01 for both TOP2A and TOP2B
(mean ± standard deviation, n = 6).Apparent Km(ATP) of TOP2B
To measure the apparent Km(ATP) of TOP2B at the concentration
of supercoiled DNA used in the ﬂuorescence anisotropy assay, the
ATP concentration was varied between 1 and 2000 lM and the
TOP2B concentration was varied between 45 and 720 ng/ml. Con-
trols were included that omitted ATP or TOP2B. All other condi-
tions were the same as above. ATP concentration had no effect
on the baseline anisotropy in the absence of TOP2B, and TOP2B
concentration had no effect on the baseline anisotropy in the ab-
sence of ATP. From the set of measurements of anisotropy change
(Danisotropy) made at each ATP concentration over a range of
TOP2B concentrations, the result was chosen that had the highest
Danisotropy in the range 0.01 to 0.10. These values were divided
by their respective TOP2B concentrations to obtain the measure-
ments of initial rates, expressed as Danisotropy/(ng/ml TOP2B).
The data were ﬁt to the Michaelis-Menten equation by nonlinear
least-squares regression to obtain Km,apparent(ATP).Effect of ATP concentration on TOP2B inhibitor IC50s
Compound concentrations ranged from 20 to 0.039 lM, except
for gemiﬂoxacin, for which the range was 400 to 0.78 lM. The ATP
and TOP2B concentrations were varied in parallel to give Danisot-
ropy  0.08–0.10 and were as follows: 20 lM ATP with 720 ng/ml
TOP2B, 100 lM ATP with 130 ng/ml TOP2B, and 1000 lM ATP with
70 ng/ml TOP2B. Other conditions used were the same as stated
previously. Assays with each pair of ATP and TOP2B concentrations
were performed on separate plates. An additional plate was in-
cluded with no ATP or TOP2B for use in artifact correction.
Table 1
Inhibitory potencies (IC50s) versus human TOP2A and TOP2B by 19 TopoII inhibitors
in the ﬂuorescence anisotropy-based assay of ATP-dependent DNA relaxation.
Inhibitor TOP2A TOP2B A/B IC50 P value
IC50 (lM) IC50 (lM) ratio
Daunorubicin 1.6 ± 0.2 1.1 ± 0.2 1.4 0.004
Doxorubicin 1.5 ± 0.2 1.1 ± 0.3 1.4 0.03
Epirubicin 1.5 ± 0.2 1.1 ± 0.1 1.4 0.06
Etoposide 8.1 ± 3.0 15 ± 6.9 0.5 0.09
Teniposide 1.4 ± 0.3 3.7 ± 1.4 0.4 0.06
Razoxane 2.0 ± 0.5 1.9 ± 0.5 1.0 0.42
Dexrazoxane 1.9 ± 0.5 2.3 ± 0.7 0.8 0.07
Amsacrine 0.7 ± 0.2 1.1 ± 0.7 0.6 0.30
Mitoxantrone 1.0 ±0.5 0.5 ± 0.2 2.0 0.10
Actinomycin D 1.6 ± 0.2 1.5 ± 0.1 1.0 0.18
Merbarone 22 ± 6 88 ± 22 0.25 0.03
Suramin 5.6 ± 1.2 4.5 ± 2.2 1.2 0.22
ICRF-193 0.41 ± 0.05 0.21 ± 0.06 2.0 0.01
Genistein 4.1 ± 1.0 3.5 ± 1.0 1.2 0.20
Bisantrene 2.5 ± 0.2 1.4 ± 0.3 1.0 0.42
XK469 4.9 ± 0.8 3.8 ± 1.2 1.3 0.22
Ciproﬂoxacin 110 ± 25 111 ± 15 1.0 0.88
Gemiﬂoxacin 20 ± 4 16 ± 4 1.2 0.20
Levoﬂoxacin 220 ± 30 190 ± 20 1.2 0.04
Means ± standard deviations of 3 replicate measurements made for the two
enzymes side-by-side on separate days are shown. P values are for two-tailed
paired t tests of the null hypothesis that there was no difference between the
TOP2Aand the TOP2B IC50s. Statistically signiﬁcant P values (60.05) are highlighted
in boldface type.
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Titration of human TOP2B concentration in the ﬂuorescence
anisotropy assay
The ATP-dependent relaxation of supercoiled plasmid DNA by
human TOP2B was measured using the same assay and under
the same conditions as previously reported for human TOP2A
[29]. The ﬂuorescence anisotropy readout increased in direct pro-
portion to the TOP2B concentration for enzyme concentrations
up to 100 ng/ml (0.56 nM monomer, molecular weight 180,000),
consistent with previous demonstrations that the change in ﬂuo-
rescence anisotropy is directly proportional to the change in the
fraction of the plasmid that is relaxed [28]. There was no anisot-
ropy change when ATP was omitted, showing that plasmid relaxa-
tion was not due to contaminating endonuclease activity (Fig. 1).
At 1000 ng/ml TOP2B in the absence of ATP, the anisotropy in-
creased by 0.01 (not shown), showing that contaminating endonu-
clease activity or background cleavable complex stabilization was
negligible under typical assay conditions. The assay provided a
usefully large anisotropy change of 0.1 and a satisfactory Z0 > 0.7
when the TOP2B concentration was 90 ng/ml. The correspondence
between the ﬂuorescence anisotropy and the degree of supercoil-
ing as measured by gel electrophoresis was demonstrated
previously [28].
Potency of human TOP2A and TOP2B inhibition by compounds
The concentrations of a diverse set of 19 commercially available
TopoII inhibitors causing 50% inhibition (IC50) of TOP2A and TOP2B
activity in the ﬂuorescence anisotropy-based assay of ATP-depen-
dent supercoiled DNA relaxation were measured side-by-side (Ta-
ble 1). The IC50s were reproducible from day to day. Although some
compounds caused interference in the assay due to compound
ﬂuorescence (daunorubicin, doxorubicin, and epirubicin) or ﬂuo-
rescence quenching (amsacrine, actinomycin D, and most severely,
mitoxantrone), it was possible to calculate IC50s for every com-
pound tested. The TOP2A IC50 values of amsacrine, ICRF-193, mer-
barone, mitoxantrone, suramin, teniposide, and etoposide were in
agreement with those previously reported using the same assay
[29].
The anthracyclines daunorubicin, doxorubicin, and epirubicin
had nearly identical IC50s, which were slightly but consistently
more potent against TOP2B than TOP2A. The difference was statis-
tically signiﬁcant (P < 0.05) for daunorubicin and doxorubicin. For
both of the epipodophyllotoxins, etoposide and teniposide, theFig. 1. The effect of human TOP2B concentration on ATP-dependent relaxation of
supercoiled plasmid as measured by the increase in ﬂuorescence anisotropy. Assay
conditions were as described in [29], except for the substitution of TOP2B for
TOP2A. The DMSO concentration was 2% by volume. Data points and error bars
represent the means and standard deviations of triplicate measurements.TOP2B IC50s were about 2-fold less potent than the TOP2A IC50s,
although the differences did not quite reach statistical signiﬁcance.
Teniposide was more potent than etoposide. Merbarone was 4-fold
more potent versus TOP2A than TOP2B, a difference that was sta-
tistically signiﬁcant. ICRF-193, in contrast was 2-fold more potent
versus TOP2B than TOP2A, a difference that was also statistically
signiﬁcant. Although mitoxantrone was 2-fold more potent versus
TOP2B than TOP2A, the difference did not reach statistical signiﬁ-
cance. None of the other compounds (razoxane, dexrazoxane,
amsacrine, actinomycin D, suramin, genistein, bisantrene, XK469,
ciproﬂoxacin, gemiﬂoxacin, or levoﬂoxacin) showed as much as a
2-fold potency difference between the two enzymes, although
the slight difference between TOP2A and TOP2B IC50s of levoﬂoxa-
cin was statistically signiﬁcant. That the inhibition by merbarone,
actinomycin D, and bisantrene may have been nonspeciﬁc due to
compound aggregation or insolubility is suggested by the very
steep, step-like shapes of their IC50 curves (not shown). For merba-
rone, this may only have been the case with TOP2B, since the
TOP2A IC50 curve was less steep.
The percentage inhibition vs compound concentration IC50
curves increased monotonically from 0 to 100% inhibition for all
the compounds for which compound interference in the assay
was inconsequential (data not shown). If there had been a signiﬁ-
cant detection of cleavable complex stabilization in the assay, it
would have resulted in inhibitor-induced DNA relaxation caused
by linearization of the plasmid, rather than the observed inhibition
of relaxation. There would, therefore, have been no apparent inhi-
bition by the topoisomerase poisons, or IC50 curves that showed
partial inhibition and a return to no inhibition at high inhibitor
concentrations, or enhancement of relaxation rather than inhibi-
tion. Since no such phenomena were observed, we conclude that
the assay does not detect cleavable complex stabilization to a
measurable extent.Apparent Km(ATP) of TOP2B
The apparent Km(ATP) for DNA relaxation by TOP2B in the
ﬂuorescence anisotropy assay, which contains 85 lg/ml DNA
Table 2
Effect of ATP concentration on TOP2B inhibitor IC50s.
IC50 at 20 lM IC50 at 100 lM IC50 at 1000 lM
Inhibitor ATP (lM) ATP (lM) ATP (lM)
Dexrazoxane >20 5.8 2.2
XK469 >20 5.9 3.7
Epirubicin 1.5 1.5 1.5
Doxorubicin 1.6 1.7 1.2
Daunorubicin 1.6 1.5 1.2
Amsacrine 2.3 1.3 1.0
ICRF-193 1.8 0.40 0.27
Mitoxantrone >1.25 1.1 0.80
Suramin 2.2 2.9 3.2
Teniposide 17 5.6 3.2
Gemiﬂoxacin 27 19 20
Actinomycin D 1.7 1.6 1.5
Genistein 7.7 3.5 3.1
Bisantrene 2.1 1.6 1.6
Razoxane 11 4.1 2.0
Results are for single determinations.
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Fig. 3. Comparison of TOP2A and TOP2B IC50s for a set of 75 related proprietary
bacterial type II topoisomerase inhibitors. Each data point represents a single IC50
measurement. Open triangles and squares show triplicate measurements for each
of 2 compounds. Data points on the borders represent IC50sP 200 lM.
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0.21 ± 0.04 mM obtained previously for TOP2A in the same assay
under identical conditions [29]. There was no evidence of the sig-
moidal response to ATP reported by Drake et al. [24]. Km(DNA)
was not investigated.
Effect of ATP concentration on TOP2B inhibitor IC50s
The effect of varying the ATP concentration from well below to
well above the Km,apparent(ATP) in the ﬂuorescence anisotropy assay
on the IC50s of the more potent examples of TOP2B inhibitors is
shown in Table 2. For some compounds, there was no signiﬁcant
effect of ATP concentration on IC50. These include the anthracy-
clines daunorubicin, doxorubicin, and epirubicin, as well as sura-
min, gemiﬂoxacin, actinomycin D, and bisantrene. For some
compounds, there was a substantial decrease in IC50 as ATP in-
creased. These include the bisdioxopiperazines dexrazoxane
(P9.3-fold lower IC50 at 1000 lM ATP than at 20 lM ATP), razox-
ane (5.6-fold), and ICRF-193 (6.6-fold), XK469 (P5.4-fold), and
teniposide (5.2-fold). Smaller ATP-dependent decreases in IC50
were seen for amsacrine (2.3-fold) and genistein (2.5-fold). For
mitoxantrone, an ATP-dependent IC50 decrease was suggested,
but interference by the compound prevented measurement of
the highest IC50 at 20 lM ATP.
Comparison of TOP2A and TOP2B IC50s for a set of bacterial type II
topoisomerase inhibitors analogs
As a demonstration of the practical application of the ﬂuores-
cence anisotropy assay, TOP2A and TOP2B IC50s were measured
in a side-by-side assay for 75 related proprietary compounds from
a bacterial type II topoisomerase inhibitor project. Fig. 3 shows that
there was a strong correlation between the TOP2A and the TOP2B
IC50s, with slightly more potent inhibition of TOP2B than TOP2A
overall (average TOP2A-to-TOP2B IC50 ratio = 1.9, standard devia-
tion = 0.7, n = 52 measurements for which both the TOP2A and
the TOP2B IC50s were <200 lM).
Discussion
The above results demonstrate the use of a simple, high-
throughput assay to simultaneously and quickly measure the
potencies of numerous inhibitors toward both human TOP2A-
and TOP2B-catalyzed ATP-dependent relaxation of supercoiledmM ATP
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Fig. 2. Apparent Km(ATP) for TOP2B in the ﬂuorescence anisotropy assay at 85 lg/
ml DNA. Each data point represents the mean and standard deviation of triplicate
measurements. The best-ﬁt value of Km,apparent(ATP) from nonlinear least-squares
regression to the Michaelis-Menten equation was 0.17 ± 0.03 mM (standard error of
ﬁt).DNA. The unique nature of the ﬂuorescence anisotropy assay is
its speed, simplicity, and convenience compared with the usual
method, agarose gel electrophoresis, allowing measurement of
IC50s versus both TOP2A and TOP2B at the same time for a large
number of inhibitors with little effort. This was done for 19 com-
pounds in triplicate (Table 1), i.e., 114 IC50s, which were measured
in half a day by one person, including calculations, using nine
384-well assay plates. The same amount of effort was required to
measure, at one time, the 150 IC50s shown in Fig. 3. To do this by
agarose gel electrophoresis would have required 57 or 75 gels,
respectively (2 IC50s/gel), with samples loaded manually. Each gel
takes a minimum of 3 h to run, although several gels can be run
in parallel and the electrophoresis can be run overnight, plus addi-
tional time is needed to stain and destain the gels. Band quantita-
tion is a laborious manual process done one lane at a time. The data
in Table 1 would take one person at least a week to collect by gel
electrophoresis and would be extremely labor-intensive. The gel-
based assay could not be scaled up to screen large compound
libraries.
It has been proposed that selective inhibition of TOP2A over
TOP2B would be preferable for anticancer drugs because TOP2B
mediates cytotoxicity [14,18] and genotoxicity [15–17]. The small
differences (64-fold) observed between TOP2A and TOP2B IC50s of
the compounds we tested, presumably due to the high degree of
sequence similarity between the isoforms, suggest that it will be
challenging to identify compounds with high isoform selectivity.
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effort by maximizing the number of compounds that could be
screened for differential inhibition in anticancer drug discovery
programs to develop a structure–activity relationship (SAR) for
the greatest degree of selective inhibition of one of the two en-
zymes. This methodology could also add value to an antibacterial
drug discovery program, especially one targeting bacterial TopoIIs,
by enabling facile testing of all the compounds in a series for un-
wanted inhibition of human TopoII enzymes that could lead to
cytotoxic and/or genotoxic side effects. The data in Fig. 3 for a ser-
ies of 75 related proprietary bacterial TopoII inhibitors show that
compounds within the series cover a wide range of TOP2A and
TOP2B inhibitory potencies, and that these potencies are highly
correlated.
Because of the high degree of sequence homology between hu-
man TOP2A and TOP2B [8], it is not surprising that there was little
difference between the inhibitory potencies of the compounds
tested toward the two enzymes in vitro. The largest IC50 ratio
was 4-fold. The fact that the IC50s varied over a 10,000-fold range
shows that the small differences between TOP2A and TOP2B IC50s
for individual inhibitors were not the result of a lack of dynamic
range of the assay for IC50 measurement. Moreover, the high corre-
lation between IC50s measured by the TOP2A ﬂuorescence anisot-
ropy assay and the gel-based assay [29] shows that the
ﬂuorescence anisotropy assay has the same ability to differentiate
between inhibitor potencies as the gel-based assay. There may be
certain modes of inhibition of the enzymes that are more likely
to produce differential inhibitor potency due to greater sequence
divergence. The C-terminus is the most divergent region between
TOP2A and TOP2B, affecting DNA binding by TOP2B but not TOP2A
[34]. Therefore compounds binding at the C-terminus might have
the greatest likelihood of being selective. The C-terminal domain
of TOP2A but not TOP2B is essential for growth of yeast in which
the natural TopoII has been replaced by one of the human enzymes
[35]. Sequence divergence between the C-terminal domains might
therefore make the TOP2A C-terminal domain a promising target
for anticancer drugs with low TopoII-related toxicity.
The ATP-dependent supercoiled DNA relaxation IC50s measured
here for doxorubicin and daunorubicin, mitoxantrone, bisantrene,
suramin, and merbarone were quite similar to those reported by
Perrin et al. [21] for inhibition of DNA decatenation by both TOP2A
and TOP2B. Also, the potency and TOP2A selectivity of merbarone
we observed were similar to previous ﬁndings [22,24]. On the
other hand, there were several discrepancies between our IC50 re-
sults and those reported elsewhere. Perrin et al. [21] reported a
high degree of selectivity of razoxane and ICRF-193 for TOP2A,
which we did not observe. Perrin et al. [21] also reported much
higher IC50s for etoposide, teniposide, genistein, amsacrine, and
dexrazoxane than we measured. The IC50 of XK469 was much high-
er and the selectivity for TOP2B much greater in the report by Gao
et al. [25] than we observed. The IC50s we measured for ciproﬂox-
acin and levoﬂoxacin were much lower than previously reported
values [36]. To some extent, these differences may be due to the
measurement of different phenomena: ATP-dependent relaxation
of supercoiled DNA versus decatenation of linked circles [21,24].
Topoisomerase poisons are represented among those compounds
for which our results are in agreement with the literature (anthra-
cyclines, mitoxantrone, bisantrene) and those compounds for
which our results differ (epipodophyllotoxins, genistein, amsa-
crine, XK469, ﬂuoroquinolones). Therefore, it is unlikely that the
discrepancies arise from an inability of our assay to correctly mea-
sure inhibition of DNA relaxation by topoisomerase poisons. As al-
ready stated, our assay is capable of measuring IC50s over a wide
dynamic range. Therefore, the smaller TOP2A vs TOP2B IC50 differ-
entials we measured for some compounds than have been previ-
ously reported are not due to the inability of the assay to detectthem. Differences in assay conditions that may affect the ionization
state of some compounds and the target site as well as compound
solubility, such as substrate concentrations, pH, and Mg2+ concen-
tration, may also contribute to the discrepancies. DNA concentra-
tion differences between assays could have substantial effects on
potencies of compounds that bind to DNA, such as the anthracy-
clines. It is important, therefore, that IC50s for TOP2A and TOP2B
inhibition are measured under identical conditions, as was the case
for our measurements.
Interference by chemical compounds with biochemical assays is
frequently observed. Some compounds, referred to as promiscuous
inhibitors, form aggregates that inhibit enzyme activity, causing
false positives [37,38]. Compound autoﬂuorescence, ﬂuorophore
quenching, and absorption of light by compounds introduce error
into measurements of inhibitor potency when the compound re-
mains in the well of the assay plate during the readout [32], as
in the case of the assay described here. The methods for identifying
false positives caused by compound aggregation and of correcting
for errors caused by interference with the readout have been de-
scribed previously [32,37,38]. Identiﬁcation of false positives
caused by compound aggregation requires increasing the enzyme
concentration and including 0.01% Triton X-100 detergent, which
is likely to be feasible for the TOP2A and TOP2B ﬂuorescence
anisotropy assays. The interference correction procedure was used
for the compound IC50 measurements in this paper. The assay has a
satisfactory signal-to-noise ratio for screening purposes, as mea-
sured by Z0 score >0.7 (see Materials and methods), although no
information is currently available regarding the rate of false posi-
tives and the extent of detection interference when screening a
large compound collection with this assay. Detection of promiscu-
ous inhibition by increasing the topoisomerase concentration,
which would require simultaneously decreasing the reaction time,
is likely achievable with the ﬂuorescence anisotropy assay. Addi-
tion of 0.01% Triton X-100 to the TOP2B ﬂuorescence anisotropy
assay to counteract promiscuous inhibition is also likely to be
achievable, since it had no effect on the TOP2A concentration re-
sponse in the same assay [29]. Thus the ﬂuorescence anisotropy as-
say is expected to be adaptable to the use of previously described
high-throughput tools to identify false positives from screens of
compound libraries.
The ability of the ﬂuorescence anisotropy assay used here to tol-
erate variation in the ATP concentration enabled us to measure the
apparent Km(ATP) for DNA relaxation by TOP2B under the same
conditions as we previously measured this parameter for TOP2A
[29]. The value was approximately the same at about 0.2 mM for
both enzymes, which is consistent with their high degree of se-
quence identity.
Investigations into the mechanisms of inhibition by TOP2A and
TOP2B inhibitors can make use of the ability to vary the ATP con-
centration in the ﬂuorescence anisotropy assay by measuring the
effect of ATP concentration on inhibitor potency. Of the inhibitors
we tested, several responded to an increase in ATP concentration
with an increase in potency (decrease in IC50). These included the
bisdioxopiperazine catalytic inhibitors dexrazoxane, razoxane,
and ICRF-193. These non-DNA-intercalating, symmetrical com-
pounds bind to a part of the interface between TOP2 subunits that
is present only when ATP or ADP is bound, the ‘‘closed clamp’’ con-
formation [39]. Thus the ATP-dependent enhancement of the po-
tency of these compounds in the ﬂuorescence anisotropy assay is
a reﬂection of their mechanism of action. Interestingly, although
the effect of bisdioxopiperazines on the ATPase activity of type II
topoisomerases has been investigated [40,41], the effect of ATP
concentration on the inhibitory potency of these compounds has
not been reported. Suramin, which blocks DNA binding to the en-
zyme [42], showed little effect of ATP on its IC50, consistent with its
mode of inhibition.
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stranded break (‘‘cleavable complex’’) by type II topoisomerase is
enhanced by ATP [43–45], it might be expected that the potencies
for inhibition of ATP-dependent supercoiled DNA relaxation for
compounds that stabilize the cleavable complex (‘‘topoisomerase
poisons’’), such as anthracyclines, epipodophyllotoxins, bisantrene,
mitoxantrone, actinomycin D, amsacrine, XK469, genistein, and
gemiﬂoxacin would increase as the ATP concentration increased.
Interestingly, this was not the case for the anthracyclines, bisant-
rene, gemiﬂoxacin, and actinomycin D (Table 2), the IC50s of which
for inhibition of TOP2B-catalyzed supercoiled DNA relaxation
showed a negligible response to the ATP concentration. In contrast,
the expected IC50 decreases with increasing ATP concentration oc-
curred for amsacrine, teniposide, genistein, and XK469. Mitoxan-
trone may also have become more potent with increasing ATP
concentration, but this intensely colored compound interfered
with the ﬂuorescence anisotropy assay such that the effect could
not be well measured.
The ability quickly to measure the ATP dependence of the inhib-
itory potency of several compounds simultaneously enables the
ﬂuorescence anisotropy assay to facilitate the discernment of sub-
tle distinctions between the mechanisms of TOP2 inhibitors. The
assay could thereby contribute to an improved understanding of
the mechanisms of TOP2 inhibitors and of the enzymes as well.
However, inhibition of TopoII-catalyzed ATP-dependent relaxation
of supercoiled DNA is caused by both topoisomerase poisons and
catalytic inhibitors. Cytotoxicity can result from both topoisomer-
ase poisoning and catalytic inhibition, whereas genotoxicity is
thought to result mainly from topoisomerase poisoning. Moreover,
catalytic inhibition can be protective against the toxicity of topoi-
somerase poisons [19]. Therefore, measuring only inhibition of
catalysis cannot by itself distinguish between compounds that
are genotoxic due to TopoII poisoning and those that are not, or
identify compounds that are protective against the toxic effects
of topoisomerase poisons. A goal for the future should be the
development of a high-throughput assay for cleavable complex
stabilization. The two assays used together would be a powerful
tool for characterizing the modes of TopoII inhibition of large num-
bers of compounds.References
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